GANX (gaintherapeutics.com) Enterprise Value-to-Revenue Coefficient

Gain Therapeutics Inc. (GANX) - corporate logo

Gain Therapeutics, Inc. (GANX) is developing therapies for neurological diseases through the synergy of computational systems and partnerships with biotech laboratories. This chart from GURU.Markets illustrates the valuation dynamics relative to revenue, where the EV-to-revenue level of 0.00 serves as the current metric. The company's revenues are based on licenses and the treatment of degenerative brain disorders, with growth potential limited only by the success of clinical trials.

Gain Therapeutics, Inc. - GANX EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

gaintherapeutics.com - analytical breakdowns and key metrics (GANX)

- current price and projected stock value:
- business market valuation indicators:
- cash and cash flow indicators:
Initial company analysis:Gain Therapeutics, Inc.
Product sample of Gain Therapeutics, Inc.

This indicator is calculated as the ratio of Enterprise Value (EV), which combines market capitalization and net debt, to annual revenue, allowing for an assessment of the real value of assets regardless of financial leverage. For Gain Therapeutics, Inc. (GANX), where academic management strictly optimizes R&D expenses, the EV/Revenue multiple serves as a metric for the monetization efficiency of its AI platform, helping investors distinguish an undervalued asset from a value trap.

Competitor analysis for Gain Therapeutics, Inc.

Enterprise Value-to-Revenue Multiple hcahealthcare.com|THC: EV/Sales Multiple|FMS - Total Company Value-to-Revenue Ratio|Company Value to Revenue SOLV|Encompass (EHC) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Universal Health Services, Inc. (UHS)|DaVita Inc. - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio RadNet Corp RDNT|EV/Sales Multiple Option Care OPCH|Surgery Partners Inc - EV/Sales Multiple|PINC (Premier Corp) - Company Value to Revenue Ratio|nationalvision.com (EYE) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Progyny|Company Value to Revenue ARDT|EV/Sales Multiple Select Medical Corporation|Company Value to Revenue ASTH (Astrana Health)|Company Value to Revenue Pediatrix MD|U.S. Physical Therapy - Company Value to Revenue|Business Value to Revenue PNTG|Organogenesis - EV/Sales Multiple|NUTX (Nutex Health) - Company Value to Revenue Ratio|AUNA (Auna) - Company Value to Revenue|Enterprise Value to Sales Volume SBC (SBC Medical Group Holdings)|Enterprise Value-to-Revenue Ratio Evolus, Inc.|Community Health Systems, Inc. (CYH) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Beauty Health (SKIN)|MediWound, Ltd. - Company Value to Revenue Ratio|EV/Sales Multiple BTMD (Biote)|Enterprise Value-to-Revenue Coefficient JYNT (The Joint Corp.)|DCGO - Enterprise Value-to-Revenue Ratio|PIII: Enterprise Value-to-Revenue Ratio|euda.com (EUDA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Basel Medical|CLGN (CollPlant Biotechnologies) - EV/Sales Multiple|EV/Sales Multiple Cuprina Holdings Limited|Enterprise Value-to-Revenue Ratio concordmedical.com (CCM)|Enterprise Value-to-Revenue Ratio AMS (American Shared Hospital)|Enterprise Value-to-Revenue Ratio MEDIROM Corp MRM|EV/Sales Multiple avalon-globocare.com ALBT|DHAI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Longevity Health Holdings XAGE|NIVF (NewGenIvf Group Limited) - Company Value to Revenue|ATI Physical Therapy Inc. - Business Value to Revenue|CMAX (caremax.com) - EV/Sales Multiple|KDLY (Kindly MD Inc) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ModivCare Corp (MODV)|Total Company Value-to-Revenue Ratio Novo Integrated Sciences|SunLink Health Systems, Inc. - Company Value to Revenue|imacholdings.comm (BACK) - Enterprise Value-to-Revenue Multiple